POU2AF2/OCA-T1 coactivates POU2F2 and defines a lineage-specific dependency in diffuse large B-cell lymphoma

Recent research has uncovered a critical lineage-specific dependency in a subset of diffuse large B-cell lymphoma (DLBCL), identified through a coactivator protein known as POU2AF2, which encodes OCA-T1. This finding was made possible by analyzing pan-cancer dependency data and patient cohorts, which revealed elevated levels of POU2AF2 in genetically aggressive DLBCL cases. When the expression of POU2AF2 was suppressed, tumor growth was significantly reduced both in laboratory tests and in living organisms.

The researchers discovered that POU2AF2 works in concert with the B-cell lineage-defining transcription factor POU2F2 (OCT2) to activate lymphocyte activation gene programs. This activation happens through direct interaction with the chromatin, a complex of DNA and proteins that make up chromosomes. By doing so, POU2AF2 sustains the malignant transcriptional networks that drive DLBCL.

In addition to these findings, the researchers identified a crucial epigenetic regulatory axis. This axis involves the lineage-specific transcription factor TCF3 and the histone methyltransferase SET1A-COMPASS. These elements drive the expression of POU2AF2 downstream of B-cell receptor signaling. Single-cell transcriptomic analysis further revealed that POU2AF2 marks and sustains an innate-like B1 B-cell population in vivo, which is believed to be a candidate cell of origin for lymphoma.

In conclusion, this study has uncovered a previously unrecognized lineage-specific transcriptional dependency in DLBCL. The research defines a POU2AF2/POU2F2 transcriptional module that is controlled by a TCF3/SET1A epigenetic network. This module is responsible for maintaining both the innate-like B-cell identity and malignant fitness in DLBCL. The identification of POU2AF2 and its associated regulatory circuitry as potential therapeutic targets opens up new avenues for treating aggressive B-cell malignancies.